ArticleCell death discovery2026
Intrinsic polyunsaturated fatty acid synthesis capacity dictates ferroptosis sensitivity under restricted arachidonic acid availability.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Ferroptosis is an iron-dependent type of regulated cell death driven by lipid peroxidation, in which polyunsaturated fatty acids (PUFAs) in membrane phospholipids serve as key substrates. Here, we identify PUFA biosynthetic capacity as a key determinant of ferroptosis sensitivity under arachidonic acid (AA)-limited conditions. Lipidomic and stable isotope-tracing analyses in human lung adenocarcinoma cell lines revealed that H1299 cells that harbor wild-type KEAP1 and are sensitive to ferroptosis have unexpectedly impaired PUFA biosynthesis and consequently low PUFA levels. Nevertheless, ferroptosis sensitivity in H1299 cells is maintained under normal culture conditions owing to an exogenous supply of AA. Culturing cells in the B27 supplement, which provides only essential fatty acids such as linoleic acid, in the presence of 1% dialyzed FBS reduced AA-containing phospholipids and rendered H1299 cells resistant to ferroptosis. In contrast, A549 cells with a KEAP1 mutation retained ferroptosis sensitivity under B27 conditions, enabled by their endogenous PUFA-synthesizing capacity. Strikingly, pharmacological inhibition of FADS2 or deletion of ELOVL5 in A549 cells phenocopied H1299 cells, conferring resistance under B27-AO conditions that was reversed by AA supplementation. These findings demonstrate that ferroptosis susceptibility is dictated by intrinsic PUFA biosynthetic capacity under AA-limited conditions resembling physiological lipid availability. Therefore, intrinsic PUFA biosynthetic capacity should be considered in ferroptosis-based cancer therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.